Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | CAN1012 |
Synonyms | |
Therapy Description |
CAN1012 is a selective TLR7 agonist, which potentially results in increased immune response, leading to antitumor activity (Journal for ImmunoTherapy of Cancer 2022;10). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CAN1012 | CAN-1012|CAN 1012 | TLR7 Agonist 11 | CAN1012 is a selective TLR7 agonist, which potentially results in increased immune response, leading to antitumor activity (Journal for ImmunoTherapy of Cancer 2022;10). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04987112 | Phase I | CAN1012 | Intratumoral CAN1012 in Subjects With Solid Tumors | Recruiting | USA | 0 |